insights_auto
Why is LGND up 3,09%?
Dive Deeperchevron_right
LGND:NASDAQ
Ligand Pharmaceuticals Inc
311,13 $
arrow_upward
+3,09%(+9,32) 1D
311,13 $
0,00% (0,00)
bedtimeAfter hours
Closed: 12 հոկ, 16:00:02 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LGND...
Open
302,50 $
High
311,86 $
Low
300,00 $
Mkt. cap
6,20 մլրդ
Avg. vol.
246,60 հզր
Volume
0,00
P/E ratio
33,09
52-wk high
326,63 $
52-wk low
175,89 $
EPS
9,40 $
Beta
1,06
Shares outstanding
19,94 մլն
No. of employees
47
Open
302,50 $
High
311,86 $
Low
300,00 $
Mkt. cap
6,20 մլրդ
Avg. vol.
246,60 հզր
Volume
0,00
P/E ratio
33,09
52-wk high
326,63 $
52-wk low
175,89 $
EPS
9,40 $
Beta
1,06
Shares outstanding
19,94 մլն
No. of employees
47
News stories
From web sources and news partners
Investing.com Australia
·
1 օր առաջ
Form 4 Ligand Pharmaceuticals Incorporated For: 11 October By Investing.com
Investing.com Australia
·
1 օր առաջ
Ligand Pharma CLO Andrew Reardon sells $1.52 million in stock By Investing.com
Profile
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
About Ligand Pharmaceuticals Inc
CEO-
Employees47
Foundedսեպ 1987
HeadquartersJupiter, Ֆլորիդա, Միացյալ Նահանգներ
Sector-
Websiteligand.com